

Bayesian hierarchical modeling of patient subpopulation oncology clinical trials

Clinical Trials

10, 720-734

DOI: [10.1177/1740774513497539](https://doi.org/10.1177/1740774513497539)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Statistical considerations associated with a comprehensive regulatory framework to address the unmet need for new antibacterial therapies. <i>Pharmaceutical Statistics</i> , 2014, 13, 222-228.	0.7	3
2	Prospects and Pitfalls of Personalizing Therapies for Sarcomas: From Children, Adolescents, and Young Adults to the Elderly. <i>Current Oncology Reports</i> , 2014, 16, 401.	1.8	9
3	The Signature Program: Bringing the Protocol to the Patient. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 124-126.	2.3	27
4	Generalizing boundaries for triangular designs, and efficacy estimation at extended follow-ups. <i>Trials</i> , 2015, 16, 522.	0.7	2
5	Current Statistical Challenges in Oncology Clinical Trials in the Era of Targeted Therapy. <i>Statistics in Biopharmaceutical Research</i> , 2015, 7, 348-356.	0.6	5
6	Bayesian dose escalation in oncology with sharing of information between patient populations. <i>Contemporary Clinical Trials</i> , 2015, 44, 56-63.	0.8	5
7	Nonparametric Bayesian Inference in Biostatistics. , 2015, , .		14
8	The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research. <i>Molecular Oncology</i> , 2015, 9, 951-959.	2.1	118
9	Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study. <i>Statistics in Biopharmaceutical Research</i> , 2016, 8, 248-257.	0.6	44
10	Group sequential designs with prospectively planned rules for subpopulation enrichment. <i>Statistics in Medicine</i> , 2016, 35, 3776-3791.	0.8	16
11	PIPELINES: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 713-729.	2.3	27
12	The Personalization of Drug Therapy for Elderly Patients. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 589-611.	0.2	0
13	Robust exchangeability designs for early phase clinical trials with multiple strata. <i>Pharmaceutical Statistics</i> , 2016, 15, 123-134.	0.7	101
14	A Bayesian adaptive phase 1 design to determine the optimal dose and schedule of an adoptive T-cell therapy in a mixed patient population. <i>Contemporary Clinical Trials</i> , 2016, 48, 153-165.	0.8	9
15	Clinical trial designs incorporating predictive biomarkers. <i>Cancer Treatment Reviews</i> , 2016, 43, 74-82.	3.4	61
16	Efficiencies of platform clinical trials: A vision of the future. <i>Clinical Trials</i> , 2016, 13, 358-366.	0.7	209
17	Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 99-119.	0.4	93
18	An efficient basket trial design. <i>Statistics in Medicine</i> , 2017, 36, 1568-1579.	0.8	82

#	ARTICLE	IF	CITATIONS
19	Adaptive designs from a Data Safety Monitoring Board perspective: Some controversies and some case studies. <i>Clinical Trials</i> , 2017, 14, 462-469.	0.7	7
20	The role of adaptive trial designs in drug development. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 727-736.	1.3	14
21	Increasing the efficiency of oncology basket trials using a Bayesian approach. <i>Contemporary Clinical Trials</i> , 2017, 63, 67-72.	0.8	40
22	Personalized medicine enrichment design for DHA supplementation clinical trial. <i>Contemporary Clinical Trials Communications</i> , 2017, 5, 116-122.	0.5	0
23	Making Sense of a Negative Clinical Trial Result: A Bayesian Analysis of a Clinical Trial of Lorazepam and Diazepam for Pediatric Status Epilepticus. <i>Annals of Emergency Medicine</i> , 2017, 69, 117-124.	0.3	8
24	Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 934-941.	2.3	71
25	Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. <i>New England Journal of Medicine</i> , 2017, 377, 62-70.	13.9	684
26	Specifying the True- and False-Positive Rates in Basket Trials. <i>JCO Precision Oncology</i> , 2017, 1, 1-5.	1.5	7
27	Clinical Trials in the Genomic Era. <i>Journal of Clinical Oncology</i> , 2017, 35, 1011-1017.	0.8	14
28	Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. <i>Journal of Clinical Oncology</i> , 2017, 35, 271-273.	0.8	110
29	BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2018, 67, 723-740.	0.5	42
30	A Bayesian basket trial design using a calibrated Bayesian hierarchical model. <i>Clinical Trials</i> , 2018, 15, 149-158.	0.7	90
31	Adaptive and platform trials in remote damage control resuscitation. <i>Journal of Trauma and Acute Care Surgery</i> , 2018, 84, S28-S34.	1.1	4
32	A hierarchical Bayesian design for randomized Phase II clinical trials with multiple groups. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 451-462.	0.4	4
33	Hierarchical models for sharing information across populations in phase I dose-escalation studies. <i>Statistical Methods in Medical Research</i> , 2018, 27, 3447-3459.	0.7	6
34	Current strategies to streamline pharmacotherapy for older adults. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 111, 432-442.	1.9	12
35	New designs for basket clinical trials in oncology. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 245-255.	0.4	23
36	Tumor-Agnostic Drug Development. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 184-187.	1.8	29

#	ARTICLE	IF	CITATIONS
37	Economic Incentives for Antibacterial Drug Development: Alternative Market Structures to Promote Innovation. , 2018, , 721-753.		2
38	Signature program: a platform of basket trials. Oncotarget, 2018, 9, 21383-21395.	0.8	36
39	Master protocol trials in oncology: Review and new trial designs. Contemporary Clinical Trials Communications, 2018, 12, 1-8.	0.5	81
40	Population-Enrichment Adaptive Design Strategy for an Event-Driven Vaccine Efficacy Trial. Statistics in Biosciences, 2018, 10, 357-370.	0.6	1
41	Bayesian basket trial design with exchangeability monitoring. Statistics in Medicine, 2018, 37, 3557-3572.	0.8	67
42	A nonparametric Bayesian basket trial design. Biometrical Journal, 2019, 61, 1160-1174.	0.6	7
43	Clinical Trial Portfolios: A Critical Oversight in Human Research Ethics, Drug Regulation, and Policy. Hastings Center Report, 2019, 49, 31-41.	0.7	23
44	Alzheimer's disease drug development pipeline: 2019. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 272-293.	1.8	546
45	Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clinical Trials, 2019, 16, 645-656.	0.7	11
46	Optimal two-stage designs for exploratory basket trials. Contemporary Clinical Trials, 2019, 85, 105807.	0.8	15
47	Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes. Biometrical Journal, 2019, 61, 1219-1231.	0.6	15
48	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAbâ€œ004) in metastatic softâ€œtissue sarcomas. Cancer, 2019, 125, 2445-2454.	2.0	19
49	Variance prior specification for a basket trial design using Bayesian hierarchical modeling. Clinical Trials, 2019, 16, 142-153.	0.7	25
50	Second-Generation P-Values, Shrinkage, and Regularized Models. Frontiers in Ecology and Evolution, 2019, 7, .	1.1	2
51	Bayesian Basket Designs for Cancer Clinical Trials. Japanese Journal of Biometrics, 2019, 39, 103-122.	0.0	0
52	Review of Statistical Methods for Biomarker-Driven Clinical Trials. JCO Precision Oncology, 2019, 3, 1-9.	1.5	3
53	Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies. JCO Precision Oncology, 2019, 3, 1-10.	1.5	1
54	Monitoring futility and efficacy in phase II trials with Bayesian posterior distributionsâ€œA calibration approach. Biometrical Journal, 2019, 61, 488-502.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Integrating subgroups with mixed-type endpoints in early phase oncology trials. <i>Statistical Methods in Medical Research</i> , 2020, 29, 498-507.	0.7	0
56	Borrowing strength and borrowing index for Bayesian hierarchical models. <i>Computational Statistics and Data Analysis</i> , 2020, 144, 106901.	0.7	7
57	A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations. <i>Pharmaceutical Statistics</i> , 2020, 19, 975-1000.	0.7	7
58	Bayesian methods for the analysis of early-phase oncology basket trials with information borrowing across cancer types. <i>Statistics in Medicine</i> , 2020, 39, 3459-3475.	0.8	15
59	Comparing Bayesian early stopping boundaries for phase II clinical trials. <i>Pharmaceutical Statistics</i> , 2020, 19, 928-939.	0.7	5
60	Flexible Bayesian subgroup analysis in early and confirmatory trials. <i>Contemporary Clinical Trials</i> , 2020, 98, 106149.	0.8	4
61	Innovative trial design in precision oncology. <i>Seminars in Cancer Biology</i> , 2022, 84, 284-292.	4.3	12
62	A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries. <i>PLoS ONE</i> , 2020, 15, e0237254.	1.1	1
63	The Joint i3+3 (Ji3+3) design for phase I/II adoptive cell therapy clinical trials. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 993-1005.	0.4	2
64	Potential Statistical Issues Between Designers and Regulators in Confirmatory Basket, Umbrella, and Platform Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 444-446.	2.3	11
65	Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy. <i>Biostatistics</i> , 2022, 23, 120-135.	0.9	24
66	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. <i>BMC Cancer</i> , 2020, 20, 523.	1.1	24
67	The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. <i>Clinical Therapeutics</i> , 2020, 42, 1330-1360.	1.1	74
68	RoBoT: a robust Bayesian hypothesis testing method for basket trials. <i>Biostatistics</i> , 2021, 22, 897-912.	0.9	19
69	Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data. <i>Statistics in Medicine</i> , 2020, 39, 1103-1124.	0.8	14
70	Bayesian adaptive basket trial design using model averaging. <i>Biostatistics</i> , 2021, 22, 19-34.	0.9	27
71	Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology. <i>Statistical Methods in Medical Research</i> , 2021, 30, 843-856.	0.7	4
72	How Many Cohorts Should Be Considered in an Exploratory Master Protocol?. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 280-285.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 248-258.	0.6	6
74	Designing and analyzing clinical trials for personalized medicine via Bayesian models. <i>Pharmaceutical Statistics</i> , 2021, 20, 573-596.	0.7	1
76	Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). <i>Statistics in Medicine</i> , 2021, 40, 2893-2921.	0.8	4
77	A Phase II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. <i>Bayesian Analysis</i> , 2021, 16, 179-202.	1.6	10
78	A Generalized Framework of Optimal Two-Stage Designs for Exploratory Basket Trials. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 286-294.	0.6	6
79	Categories, components, and techniques in a modular construction of basket trials for application and further research. <i>Biometrical Journal</i> , 2021, 63, 1159-1184.	0.6	8
80	A new basket trial design based on clustering of homogeneous subpopulations. <i>Journal of Biopharmaceutical Statistics</i> , 2021, 31, 425-447.	0.4	5
81	Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials. <i>Contemporary Clinical Trials</i> , 2021, 107, 106460.	0.8	10
82	Incorporating covariates information in adaptive clinical trials for precision medicine. <i>Pharmaceutical Statistics</i> , 2022, 21, 176-195.	0.7	3
83	Elastic priors to dynamically borrow information from historical data in clinical trials. <i>Biometrics</i> , 2023, 79, 49-60.	0.8	21
84	Flexible Conditional Borrowing Approaches for Leveraging Historical Data in the Bayesian Design of Superiority Trials. <i>Statistics in Biosciences</i> , 0, , 1.	0.6	0
85	A Bayesian Method for the Detection of Proof of Concept in Early Phase Oncology Studies with a Basket Design. <i>Statistics in Biosciences</i> , 2020, 12, 167-179.	0.6	5
86	A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. <i>Oncotarget</i> , 2020, 11, 1235-1243.	0.8	3
87	Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample. <i>PLoS ONE</i> , 2021, 16, e0258093.	1.1	3
88	Optimal one-stage design and analysis for efficacy expansion in Phase I oncology trials. <i>Clinical Trials</i> , 2021, 18, 673-680.	0.7	4
89	Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers. <i>Statistics in Medicine</i> , 2022, 41, 298-309.	0.8	5
90	Biomarker-Driven Adaptive Design. , 2015, , 311-326.		0
91	Trial Designs and Biostatistics for Molecular-Targeted Agents. , 2017, , 915-924.		0

#	ARTICLE	IF	CITATIONS
92	Cancer Clinical Trials Based on Master Protocol. Japanese Journal of Biometrics, 2019, 39, 85-101.	0.0	1
93	Review of Phase II Basket Trials for Precision Medicine. Annals of Biostatistics & Biometric Applications, 2019, 2, .	0.2	1
94	Bayesian adaptive design for concurrent trials involving biologically related diseases. Biostatistics, 2022, 23, 1007-1022.	0.9	2
95	Patient Benefits from Innovative Designs in Rare Diseases. , 2021, , 147-160.		2
97	Interim Analysis in Clinical Trials. , 2021, , 1-20.		0
98	A Comparison of Different Approaches to Bayesian Hierarchical Models in a Basket Trial to Evaluate the Benefits of Increasing Complexity. Statistics in Biopharmaceutical Research, 2022, 14, 324-333.	0.6	3
99	Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan. Pharmaceutical Statistics, 2022, , .	0.7	2
101	Bayesian basket trial design with false-discovery rate control. Clinical Trials, 2022, , 174077452110736.	0.7	4
102	Novel clinical trial design and analytic methods to tackle challenges in therapeutic development in rare diseases. Annals of Translational Medicine, 2021, .	0.7	3
103	Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial. BMC Medical Research Methodology, 2022, 22, 49.	1.4	3
104	High flow nasal catheter therapy versus non-invasive positive pressure ventilation in acute respiratory failure (RENOVATE trial): protocol and statistical analysis plan. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2022, 24, 61-70.	0.0	2
105	Monotonicity conditions for avoiding counterintuitive decisions in basket trials. Biometrical Journal, 0, , .	0.6	1
106	Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health Technology Assessment, 2021, 25, 1-228.	1.3	7
107	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. Cancer Discovery, 2022, 12, 1435-1448.	7.7	28
108	Efficiency of a randomized confirmatory basket trial design constrained to control the family wise error rate by indication. Statistical Methods in Medical Research, 2022, 31, 1207-1223.	0.7	7
109	A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints. Biometrics, 2023, 79, 1459-1471.	0.8	1
110	PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints. Journal of Biopharmaceutical Statistics, 2022, 32, 567-581.	0.4	2
111	Bayesian Additive Regression Trees (BART) with covariate adjusted borrowing in subgroup analyses. Journal of Biopharmaceutical Statistics, 0, , 1-14.	0.4	4

#	ARTICLE	IF	CITATIONS
112	Bayesian local exchangeability design for phase II basket trials. <i>Statistics in Medicine</i> , 0, , .	0.8	2
113	Bayesian sample size determination in basket trials borrowing information between subsets. <i>Biostatistics</i> , 0, , .	0.9	2
114	Interim Analysis in Clinical Trials. , 2022, , 1083-1102.		0
115	An adaptive biomarker basket design in phase <sc>II</sc> oncology trials. <i>Pharmaceutical Statistics</i> , 2023, 22, 128-142.	0.7	2
116	Challenges, opportunities, and innovative statistical designs for precision oncology trials. <i>Annals of Translational Medicine</i> , 2022, 10, 1038-1038.	0.7	2
117	Innovations in Clinical Development in Rare Diseases of Children and Adults: Small Populations and/or Small Patients. <i>Paediatric Drugs</i> , 2022, 24, 657-669.	1.3	1
118	Design and analysis of umbrella trials: Where do we stand?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
119	Bayesian Modelling Strategies for Borrowing of Information in Randomised Basket Trials. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2022, 71, 2014-2037.	0.5	5
120	Shotgun-2: A Bayesian phase I/II basket trial design to identify indication-specific optimal biological doses. <i>Statistical Methods in Medical Research</i> , 0, , 096228022211290.	0.7	0
121	Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review. <i>BMC Medical Research Methodology</i> , 2022, 22, .	1.4	0
122	Bayesian hierarchical models for adaptive basket trial designs. <i>Pharmaceutical Statistics</i> , 2023, 22, 531-546.	0.7	1
123	Bayesian optimal phase <sc>II</sc> designs with dualâ€ criterion decision making. <i>Pharmaceutical Statistics</i> , 2023, 22, 605-618.	0.7	4
124	IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy. <i>BMC Medical Research Methodology</i> , 2023, 23, .	1.4	1
125	A win ratio-based framework to combine multiple clinical endpoints in exploratory basket trials. <i>Journal of Biopharmaceutical Statistics</i> , 2024, 34, 251-259.	0.4	0
126	Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol. <i>Therapeutic Innovation and Regulatory Science</i> , 2023, 57, 823-838.	0.8	2
127	A confirmatory basket design considering non-inferiority and superiority testing. <i>Journal of Biopharmaceutical Statistics</i> , 2024, 34, 205-221.	0.4	0
128	Introduction to Basket Trials. , 2023, , 149-200.		0
129	Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval. <i>IScience</i> , 2023, 26, 106694.	1.9	1

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------